BURBANK, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Imaging3™, Inc. (the “Company”) (OTC Pink:IGNG) announces today that FINRA’s Department of Market Operations has assigned the trading symbol “IGNG” to the Company’s Common Stock and, as a result it is now approved for trading on the OTCPink market under the ticker symbol IGNG.
Mr. Dane Medley, Chairman/CEO of Imaging3 commented, “We are gratified that FINRA has approved our application and assigned our new trading symbol to our Company. After more than four years during which our stock was not quoted or trading due to our Chapter 11 reorganization, our shareholders may once again trade their IGNG shares and members of the public are free to buy and sell shares of our common stock as they see fit based upon publicly available information.”
In December 2015 and January 2016 the Company filed all of the reports required to be filed by it under SEC rules for the years ended December 31, 2013 and 2014. On April 25, 2016 the Company filed its annual report on Form 10-K for the year ended December 31, 2015. On May 16, 2016 the Company filed its quarterly report on Form 10-Q for the period ending March 31, 2016. Last Friday, the Company filed its quarterly report on Form 10-Q for the period ending June 30, 2016. As a result, the Company is current in its SEC reporting obligations for calendar 2013 through June 30, 2016. Mr. Medley stated, “We are extremely pleased that we have completed the painstaking task of becoming current in our SEC reporting obligations, thereby giving the public transparent insight into the Company’s current financial position and results of operations. The public will now be able see what has occurred over the past three years as the Company went through its reorganization and attendant litigation and to rationally evaluate the many risks of an investment in the Company.”
The Company intends to provide ongoing updates of relevant material information to the public in the form of appropriate filings and press releases, all of which will be available on EDGAR, the OTCMarkets website and our Company website, www.imaging3.com , under the news tab at the top of the page.
About Imaging3
Imaging3, Inc., founded in 1993, has developed a proprietary and patented medical imaging technology that produces 3D medical diagnostic images of virtually any part of the human body in both single 3D Safe-Scan and Continuous 3D Scan mode. Because these 3D images are constructed in real time, they will able to be used for any current or new medical procedures on a given patient in which multiple frames of reference are required to safely and optimally perform medical procedures on or in the human body, if and when the Company obtains FDA approval of specific applications of its technology. However, the Company has not yet reapplied for FDA
approval of any application of its technology (which FDA approval was denied in 2013) and there can be no assurance that the Company will obtain sufficient funding to reapply for any FDA approval or that, even if such funding is achieved, that the Company will ever receive FDA approval of any possible application of its technology.
Visit the company’s website at http://www.imaging3.com for detailed information about the Company’s technology and the many imaging products that might possibly be based upon the Company’s technology.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, failure to consummate desired business combinations or transactions, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently, unavailability of financing for the Company or its customers, product malfunction, potential product liability claims, and other factors detailed in reports filed by the Company.
Contact: Dane Medley at: Imaging3 Inc. 3022 North Hollywood Way Burbank CA, 91506 800-900-9729 ex 113
